| Rheumatoid Arthritis
Purified Cortrophin Gel vs Ruxience
Side-by-side clinical, coverage, and cost comparison for rheumatoid arthritis.Deep comparison between: Purified Cortrophin Gel vs Ruxience with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRuxience has a higher rate of injection site reactions vs Purified Cortrophin Gel based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Ruxience but not Purified Cortrophin Gel, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Purified Cortrophin Gel
Ruxience
At A Glance
SC/IM injection
Corticotropin (ACTH)
IV infusion
CD20-directed cytolytic antibody
Indications
- Arthritis, Psoriatic
- Rheumatoid Arthritis
- Ankylosing spondylitis
- Primary gout
- Lupus Erythematosus, Systemic
- Polymyositis
- Stevens-Johnson Syndrome
- Psoriasis
- Dermatitis, Atopic
- Serum Sickness
- Allergic Conjunctivitis
- Keratitis
- Iritis
- Iridocyclitis
- Uveitis
- Optic Neuritis
- Chorioretinitis
- Sarcoidosis
- Nephrotic Syndrome
- Multiple Sclerosis
- Lymphoma, Non-Hodgkin
- Chronic Lymphocytic Leukemia
- Rheumatoid Arthritis
- Granulomatosis with polyangiitis
- Microscopic Polyarteritis
- Pemphigus Vulgaris
Dosing
Arthritis, Psoriatic, Rheumatoid Arthritis, Ankylosing spondylitis, Primary gout, Lupus Erythematosus, Systemic, Polymyositis, Stevens-Johnson Syndrome, Psoriasis, Dermatitis, Atopic, Serum Sickness, Allergic Conjunctivitis, Keratitis, Iritis, Iridocyclitis, Uveitis, Optic Neuritis, Chorioretinitis, Sarcoidosis, Nephrotic Syndrome Dose individualized based on disease severity, plasma and urine corticosteroid levels, and patient response; administer SC or IM; verify adrenal responsiveness prior to treatment (up to 80 units as a single injection); chronic doses above 40 units daily associated with uncontrollable adverse effects.
Multiple Sclerosis 80-120 units daily SC or IM for 2-3 weeks for acute exacerbations.
Lymphoma, Non-Hodgkin 375 mg/m2 IV; once weekly for 4 or 8 doses (relapsed/refractory), on Day 1 of each chemotherapy cycle for up to 8 doses (previously untreated follicular or DLBCL), or every 8 weeks for 12 doses as single-agent maintenance.
Chronic Lymphocytic Leukemia 375 mg/m2 IV on Day 1 of Cycle 1, then 500 mg/m2 IV on Day 1 of Cycles 2-6 in combination with fludarabine and cyclophosphamide, every 28 days.
Rheumatoid Arthritis Two 1,000 mg IV infusions separated by 2 weeks (one course) every 24 weeks or based on clinical evaluation, but not sooner than every 16 weeks, in combination with methotrexate.
Granulomatosis with polyangiitis, Microscopic Polyarteritis Induction: 375 mg/m2 IV once weekly for 4 weeks; follow-up: two 500 mg IV infusions separated by 2 weeks, then 500 mg IV every 6 months based on clinical evaluation, in combination with glucocorticoids.
Pemphigus Vulgaris Two 1,000 mg IV infusions separated by 2 weeks plus tapering glucocorticoids; maintenance: 500 mg IV at Month 12 and every 6 months thereafter; relapse: 1,000 mg IV, no sooner than 16 weeks after the previous infusion.
Contraindications
- Intravenous administration
- Scleroderma
- Osteoporosis
- Systemic fungal infections
- Ocular herpes simplex
- Recent surgery
- History of or presence of a peptic ulcer
- Congestive heart failure
- Hypertension
- Sensitivity to proteins derived from porcine sources
- Primary adrenocortical insufficiency
- Adrenocortical hyperfunction
—
Adverse Reactions
Fluid and Electrolyte Sodium retention, hypokalemic alkalosis, fluid retention, calcium loss, potassium loss
Musculoskeletal Muscle weakness, loss of muscle mass, steroid myopathy, osteoporosis, vertebral compression fractures, aseptic necrosis of femoral and humeral heads, pathologic fracture of long bones
Gastrointestinal Peptic ulcer with possible perforation and hemorrhage, abdominal distention, ulcerative esophagitis, pancreatitis
Dermatologic Injection site reactions, impaired wound healing, increased sweating, thin fragile skin, suppression of skin test reactions, petechiae and ecchymoses, acne, hyperpigmentation, facial erythema
Cardiovascular Hypertension, congestive heart failure, necrotizing angiitis
Neurological Convulsions, increased intracranial pressure with papilledema, headache, vertigo
Endocrine Menstrual irregularities, Cushingoid state, suppression of growth in children, secondary adrenocortical and pituitary insufficiency, decreased carbohydrate tolerance, manifestations of latent diabetes mellitus, increased requirements for insulin or oral hypoglycemic agents, hirsutism
Ophthalmic Posterior subcapsular cataracts, increased intraocular pressure, glaucoma with possible damage to optic nerve, exophthalmos
Metabolic Negative nitrogen balance due to protein catabolism
Allergic Dizziness, nausea and vomiting, skin reactions, anaphylaxis (anaphylactic shock, urticaria, respiratory compromise, edema)
Miscellaneous Weight gain, abscess, development of antibodies and loss of stimulatory effect
Most common (>=25%) Infusion-related reactions, fever, lymphopenia, chills, infection, asthenia (NHL); infusion-related reactions, neutropenia (CLL).
Serious Infusion-related reactions, severe mucocutaneous reactions, hepatitis B reactivation with fulminant hepatitis, progressive multifocal leukoencephalopathy, tumor lysis syndrome, infections, cardiovascular adverse reactions, renal toxicity, bowel obstruction and perforation.
Postmarketing Prolonged pancytopenia, marrow hypoplasia, late-onset neutropenia, fatal cardiac failure, uveitis, optic neuritis, systemic vasculitis, pleuritis, lupus-like syndrome, serum sickness, polyarticular arthritis, vasculitis with rash, viral infections including PML, Kaposi's sarcoma progression, severe mucocutaneous reactions, pyoderma gangrenosum, bowel obstruction and perforation, fatal bronchiolitis obliterans, fatal interstitial lung disease, PRES/RPLS.
Pharmacology
Purified Cortrophin Gel is an anterior pituitary hormone (corticotropin/ACTH) that stimulates the functioning adrenal cortex to produce and secrete adrenocortical hormones; it is formulated as a porcine-derived purified ACTH in a sterile gelatin solution for prolonged activity.
Rituximab-pvvr is a chimeric monoclonal antibody that targets the CD20 antigen on pre-B and mature B-lymphocytes, mediating B-cell lysis through complement dependent cytotoxicity (CDC) and antibody dependent cell mediated cytotoxicity (ADCC).
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Purified Cortrophin Gel
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (1/12) · Qty limit (0/12)
Ruxience
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (0/12)
UnitedHealthcare
Purified Cortrophin Gel
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (0/8) · Qty limit (0/8)
Ruxience
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Purified Cortrophin Gel
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Ruxience
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Purified Cortrophin Gel.
$0/fillfill
Ruxience Co-Pay Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Purified Cortrophin GelView full Purified Cortrophin Gel profile
RuxienceView full Ruxience profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.